Purple Book reference family · 351(a) biologic
COVID-19 Vaccine, Adjuvanted (NUVAXOVID)
COVID-19 Vaccine, Adjuvanted is an FDA-licensed reference biologic from Sanofi Vaccines US Inc..
351(a) biologicBLA 125817 Sanofi Vaccines US Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2025
Reference product
Originator biologic
351(a)BLA 125817
NUVAXOVID COVID-19 Vaccine, Adjuvanted
Sanofi Vaccines US Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference COVID-19 Vaccine, Adjuvanted product.
1 yr 3 mo ago
COVID-19 Vaccine, Adjuvanted: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for COVID-19 Vaccine, Adjuvanted.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
